Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001140361-25-000626
Chunk: 9

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B3
Chunk 9
---
03, and our telephone number is (301) 348-8698.

<div align='center'>6</div>

TABLE OF CONTENTS

THE OFFERING Common Stock Offered By Us Shares of our Common Stock having an aggregate offering price of up to $100,000,000. Common Stock to be Outstanding After this Offering Up to 28,866,703 shares of our Common Stock, assuming the sale of up to 4,970,178 shares of our Common Stock in this offering at a price of $20.12 per share, which was the closing price of our Common Stock on Nasdaq on December 12, 2024. The actual number of shares of Common Stock issued in this offering will vary depending on how many shares of our Common Stock we choose to sell and the prices at which such sales occur. Plan of Distribution “At the market offering” that may be made from time to time on Nasdaq or other existing trading market for our Common Stock through our agent, Leerink Partners. See the section entitled “ Plan of Distribution” on page 18of this prospectus. Use of Proceeds We intend to use the net proceeds of this offering for working capital and general corporate purposes, including advancement of our product candidate pipeline. See the section entitled “ Use of Proceeds” on page 10of this prospectus. Risk Factors See “ Risk Factors” beginning on page 9of this prospectus and the other information included in, or incorporated by reference into, this prospectus for a discussion of certain factors you should carefully consider before deciding to invest in shares of our Common Stock. Nasdaq Symbol RNAC The number of shares of our Common Stock to be outstanding immediately after this offering is based on 23,896,525 shares of our Common Stock outstanding as of September 30, 2024. The number of shares outstanding as of September 30, 2024 excludes as of such date:

| • | 5,544,719 shares of Common Stock issuable upon the conversion of 166,341.592 shares of Series A Preferred Stock outstanding as of September 30, 2024; |

| • | 437,927 shares of Common Stock issuable upon the conversion of 437,927 shares of Series B Preferred Stock outstanding as of September 30, 2024; |

| • | 586,800 shares of Common Stock issuable upon the exercise of stock options outstanding as of September 30, 2024, at a weighted-average exercise price of $19